Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study

Inclusion Criteria

• •Adults age 18 or older
• •Prior allogeneic stem cell transplant, with any graft source, donor type, and GVHD prophylaxis
• •No evidence of persistent or progressive malignancy at the time of enrollment
• •Agrees to be evaluated at the transplant center before a new line of treatment is started (may be concurrent with the enrollment visit), and later between 2-6 weeks, 3 months and 6 months after index treatment is started or if an additional new therapy is started before 6 months
• •Signed, informed consent